Hidradenitis Suppurativa Clinical Trials in Toronto, Ontario
9 recruitingToronto, Ontario, Canada
Showing 1–9 of 9 trials
Recruiting
Phase 2
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Hidradenitis Suppurativa
Pfizer240 enrolled54 locationsNCT07228390
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled101 locationsNCT06959225
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
Hidradenitis Suppurativa
Novartis Pharmaceuticals142 enrolled11 locationsNCT07282015
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled316 locationsNCT06855498
Recruiting
Phase 2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Sanofi208 enrolled69 locationsNCT07170917
Recruiting
Phase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Incyte Corporation40 enrolled27 locationsNCT07213973
Recruiting
Phase 2Phase 3
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
AbbVie1,280 enrolled279 locationsNCT06468228
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis Suppurativa
AbbVie1,328 enrolled285 locationsNCT05889182